Why It Matters
CurePSP Inc. filed a New client Registration signed Sept. 4 that lists two in-house lobbyists on health, environmental, and medical research issues. The filing puts the group's own staff on record on federal research funding, an area its earlier reports covered through an outside firm.
The registration carries a $0 filing amount. Its specific-issues text covers fiscal year 2027 appropriations for progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and multiple system atrophy (MSA), plus H.R. 7779, the HEALTHY BRAINS Act, and resolutions H.Res. 1318 and S.Res. 752.
CurePSP is not new to federal lobbying. Its earlier reports list one outside firm, Faegre Drinker Biddle & Reath LLP, first reported for the second quarter of 2025 and most recently for the second quarter.
By the Numbers
The firm has reported $10,000 for each quarter from the second-quarter report to the second-quarter amendment of 2025. The amendment is the valid version of that quarter's report because it is the latest one.
The registration lists Julie Balasalle (Senior Manager, Community Advocacy) and Nora Wong (Associate Director, Public Policy). Neither appears among the lobbyists on the earlier filings, which list five others, none of whom appears on this registration.
Broader Context
CurePSP reported that it held a bipartisan congressional briefing in March with representatives Suhas Subramanyam and Gus Bilirakis on research into PSP, CBD and MSA. It said its priorities included passage of the HEALTHY BRAINS Act and more federal funding for atypical parkinsonian diseases.
H.R. 7779 was introduced March 3 in the 119th Congress. It would direct the Department of Health and Human Services (HHS) to set up research, training, and health-information programs on environmental risk factors for neurodegenerative diseases. Congress.gov lists it as referred to the House Energy and Commerce Committee.
CurePSP says language it submitted was included in the House fiscal year 2027 Labor-HHS appropriations report, encouraging the National Institute of Neurological Disorders and Stroke (NINDS) to develop funding opportunities for people with PSP and CBD.
The Congressional Research Service (CRS) reported Sept. 8 that full-year fiscal year 2027 Labor-HHS funding had not been enacted. A continuing resolution provided temporary funding through Dec. 11 at fiscal year 2026 rates. The House committee's bill proposed $189.3 billion in regular discretionary appropriations, and the Senate Appropriations Committee had not marked up its version.
H.Res. 1318, introduced May 21, supports designating May 2026 as PSP and CBD Awareness Month. It was referred to the House Energy and Commerce Committee.
Competitive Landscape
Mirum Pharmaceuticals Inc. hired LMH Strategic Solutions LLC on Sept. 4 to lobby on health issues.
WuXi AppTec Sales LLC hired Sander Lurie Consulting LLC on Sept. 3 to lobby on health issues.
The Bottom Line
The registration adds in-house lobbyists to federal research funding work that the earlier reports tracked through an outside firm. The next dated point in the record is Dec. 11, the end date of the continuing resolution described in the CRS report.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article
